Stocklytics Platform
Asset logo for symbol EBS
Emergent BioSolutions
EBS58
$10.89arrow_drop_down9.02%-$1.08
Asset logo for symbol EBS
EBS58

$10.89

arrow_drop_down9.02%

Performance History

Chart placeholder
Key Stats
Open$11.63
Prev. Close$11.97
EPS-11.22
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range10.63
11.94
52 Week Range1.42
15.10
Ratios
Revenue-
EPS-11.22

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Emergent BioSolutions (EBS)

Emergent BioSolutions Inc (EBS) is a global specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. The company focuses on the development, manufacturing, and commercialization of vaccines, therapeutics, and other biologics for emerging infectious diseases and other public health threats. With a mission to protect and enhance life, Emergent BioSolutions has established itself as a leader in the biodefense and public health sectors.
Emergent BioSolutions has a rich history dating back to its founding in 1998. Over the years, the company has grown both organically and through strategic acquisitions, solidifying its position as a key player in the biopharmaceutical industry. With a diverse portfolio of products and services, Emergent BioSolutions has become a trusted partner to governments, healthcare organizations, and other stakeholders around the world.
Websitecall_made
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Headquarters
Gaithersburg
Employees
2500
Exchange
NYSE
add Emergent BioSolutions to watchlist

Keep an eye on Emergent BioSolutions

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the 52-week high and low for Emergent BioSolutions (EBS)?

For Emergent BioSolutions (EBS), the 52-week high is $15.1, which is 38.66% from the current price. The 52-week low is $1.42, the current price is 666.9% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is Emergent BioSolutions 's (EBS) price per share?

The current price per share for Emergent BioSolutions (EBS) is $10.89. The stock has seen a price change of -$1.08 recently, indicating a -9.02% change. This reflects the stock's recent market performance and investor sentiment.
help

Is Emergent BioSolutions (EBS) a growth stock?

Emergent BioSolutions (EBS) has shown an average price growth of -3.67% over the past three years. It has received a score of 94 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Emergent BioSolutions as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Emergent BioSolutions (EBS) stock price performance year to date (YTD)?

As of the latest data, Emergent BioSolutions (EBS) has a year-to-date price change of 320.46%. Over the past month, the stock has experienced a price change of 21%. Over the last three months, the change has been 63.27%. Over the past six months, the figure is 103.17%. Looking at a longer horizon, the five-year price change stands at -80.32%.
help

Is Emergent BioSolutions (EBS) a profitable company?

Emergent BioSolutions (EBS) has a net income of -$760.5M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 27.88% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 24.51% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $292.5M. Operating income is noted at -$172M. Furthermore, the EBITDA is -$4.8M.
help

What is the market capitalization of Emergent BioSolutions (EBS)?

Emergent BioSolutions (EBS) has a market capitalization of $570.66M. The average daily trading volume is 10.98, indicating the stock's liquidity and investor engagement.

News

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS
EMERGENT BIOSOLUTIONS INC.
CLASS ACTION SETTLEMENT
SECURITIES LITIGATION
Oct 25, 2024

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS

Lipid Nanoparticles Market Research 2024 - Global Forecast to 2029: Increasing Use of Lipid Nanoparticles in Anti-Cancer Research and Growing Demand for Advanced Drug Delivery Systems
LIPID NANOPARTICLES
ANTI-CANCER
RNA-BASED THERAPIES
DRUG DELIVERY
Oct 7, 2024

Lipid Nanoparticles Market Research 2024 - Global Forecast to 2029: Increasing Use of Lipid Nanoparticles in Anti-Cancer Research and Growing Demand for Advanced Drug Delivery Systems

$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region
INFLUENZA VACCINE
MARKET GROWTH
GOVERNMENT INITIATIVES
VACCINE DEVELOPMENT
Sep 9, 2024

$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region

OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing
OAK HILL ADVISORS
EMERGENT BIOSOLUTIONS
TERM LOAN FACILITY
CREDIT FACILITY REFINANCING
FINANCIAL STABILIZATION
Sep 4, 2024

OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MILESTONE PHARMACEUTICALS
JOSEPH PAPA
CARDAMYST
PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Sep 4, 2024

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
ACAM2000
MPOX
SMALLPOX
VACCINE
FDA APPROVAL
Aug 29, 2024

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level